Premium
[P4–432]: CONSEQUENCES OF INCREASED TOMM40 EXPRESSION ON CELLULAR ENERGETICS
Author(s) -
Gottschalk William Kirby,
Zeitlow Kahli,
Charamalbous Lefko,
Ng Isaac,
Gagrani Sonal,
Mihovilovic Mirta,
Saunders Ann,
Rock Daniel,
Lou Shuhong,
Roses Allen
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.592
Subject(s) - biology , microbiology and biotechnology , mitochondrion , western blot , transfection , gene , biochemistry
neflamapimod for inhibition of cytokine production (Duffy, 2011), and correlates well with dose/concentration-response seen for episodic memory in the human clinical studies. Conclusions: The findings provide the first evidence that p38a antagonism could be a means to therapeutically target Alzheimer-related endosomal dysfunction. Further, the correlation between in vitro potency of neflamapomid on reversing endolysosomal dysfunction with clinical dose-response suggests that this pharmacological effect, rather than anti-inflammatory activity, may underlie the clinical activity of neflamapimod on episodic memory.